2024 | Australia | Randomized phase 2 and 3 trial
Grimison P et al. Journal of Clinical Oncology. 2024;42:4040-4050.
Methods: The combined analysis included 147 evaluable adults with chemotherapy-related nausea or vomiting despite guideline-consistent preventive medicines. Oral THC/CBD capsules or placebo were added to antiemetic care during a subsequent chemotherapy cycle.
Findings: Complete response, defined as no vomiting or retching and no rescue medication over 120 hours, occurred in 24% with THC/CBD versus 8% with placebo. Sedation, dizziness, and transient anxiety were more frequent with active treatment.
Limitations: Enrollment fell below the planned 250 participants. The study addressed refractory symptoms with a specific adjunctive formulation. It does not show that cannabis should replace standard antiemetics or that it treats the cancer itself.
